Maddocks has advised the Australian Nuclear Science and Technology Organisation (ANSTO) on a new long-term IP and technology licence agreement with leading German radiopharmaceutical biotech company…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
